Previous 10 | Next 10 |
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Patrick Finn, Ph.D., president and COO of Twist Bioscience, will participate in the Innovation Across Drug Disco...
2023-08-06 00:56:20 ET Summary Twist Bioscience's fiscal Q3 results show increased revenue and orders, innovative developments, and concerns over net losses and expenses. The company's future plans focus on growth through new manufacturing sites, product expansions, and hiring, wi...
2023-08-04 18:24:06 ET Twist Bioscience Corporation (TWST) Q3 2023 Results Conference Call August 04, 2023 08:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs and EGS Officer Dr. Emily Leproust - CEO and Co-Founder Jim Thorburn - CFO Co...
2023-08-04 13:21:39 ET Shares of Twist Bioscience (NASDAQ: TWST) were up more than 14% as of 1 p.m. on Friday after the company reported third-quarter earnings before the markets opened on Friday. The stock is up less than 1% so far this year. Twist is a biotech company that...
2023-08-04 07:32:09 ET Twist Bioscience press release ( NASDAQ: TWST ): Q3 GAAP EPS of -$1.01 beats by $0.13 . Revenue of $63.74M (+13.6% Y/Y) beats by $3.05M . Total orders received for the third quarter of fiscal 2023 were $63.8 million compared to $59.7 mill...
-- Record revenue of $63.7M in 3QFY23; Increase of 14% over $56.1M in Fiscal 2022 -- -- Orders increased 7% in 3QFY23 over fiscal 2022 to $63.8M -- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic D...
2023-08-03 11:45:32 ET Twist Bioscience ( NASDAQ: TWST ) is scheduled to announce Q3 earnings results on Friday, August 4th, before market open. The consensus EPS Estimate is -$1.06 (+1.9% Y/Y) and the consensus Revenue Estimate is $60.69M (+8.2% Y/Y). Over the last 2 ...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2023 third quarter ended June 30, 2023, before the opening of...
2023-07-18 09:50:16 ET Cathie Wood is one of the most successful investors of our time. Her flagship fund, Ark Innovation ETF (NYSEMKT: ARKK) , has already delivered a market-beating 59% return on capital so far this year. At its peak less than two years ago, the fund was up by over...
Cancer Research Horizons is the innovation arm of Cancer Research UK Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Cancer Research Horizons , the innovation en...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...